Your workflow deserves better results. In one week, join us for an in-depth look at how MaxCyte’s Flow Electroporation® technology delivers unmatched performance for transient and stable engineering — from small-scale experiments to large-scale runs. 📅 Thursday, Sept 4 | 4–5pm ET Speaker: Peter Gee, PhD | Regional Manager, Field Applications Scientists, APAC, MaxCyte We’ll compare traditional delivery methods to electroporation, and share new approaches that can accelerate your development timeline by weeks. Register before it starts: https://bit.ly/3Jsyzye #GeneEditing #Electroporation #CellEngineering #LifeSciences #CRISPR #GeneTherapy #CellTherapy
MaxCyte, Inc.
Biotechnology
Rockville, Maryland 10,230 followers
Let's Build Better Cells Together
About us
We invest in our partners early on, working side by side in optimizing their processes to derisk their path to the clinic faster. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.
- Website
-
http://www.maxcyte.com
External link for MaxCyte, Inc.
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Rockville, Maryland
- Type
- Public Company
- Founded
- 1999
- Specialties
- Vaccine Development, Protein Production, Transfection, Cell Therapy, Gene Therapy, Cancer, Immunotherapy, Electroporation, MyExpertPlatform, Tcell, NKcell, Bispecifics, Gene Editing, Cancer Research, Immuno-oncology, Stem Cell, CARMA, Cell Engineering, Biotechnology, Life Sciences, and Innovation
Locations
-
Primary
Get directions
9713 Key West Ave
Suite 400
Rockville, Maryland 20850, US
Employees at MaxCyte, Inc.
-
James Brady
Senior Vice President, Technical Applications & Customer Support at MaxCyte, Inc.
-
Rekha Hemrajani
-
Bryan Hays
-
Jay Gelfman, MBA
Senior Vice President - Operations at MaxCyte | Senior Global Finance and Operations Executive | Organization and Capability Builder | Collaborative…
Updates
-
In this latest Biocompare feature, MaxCyte's SVP of Technical Applications & Customer Support, James Brady, PhD, shares insights on advancing upstream manufacturing for cell-based gene therapies. In it he highlights: - How advanced process analytics, like real-time, in-line sensors, are transforming process monitoring with feedback loops that speed development and boost efficacy. - How optimized cell isolation and expansion protocols, guided by advances in cell biology and immunology, are ensuring maximal therapeutic potency. Read the article: https://bit.ly/478hLXb #GeneTherapy #CellTherapy #Bioprocessing #UpstreamManufacturing #MaxCyte #ProcessAnalytics
-
Last chance for some summer networking! We’re kicking off the MaxCyte x KACTUS x I-270 Innovation LABS summer happy hour tomorrow at 4:00pm in Frederick, MD. Expect: ✔ Great conversations ✔ Delicious hors d’oeuvres & drinks ✔ Exciting raffle prizes Don’t miss your chance to connect with the local life science community in a relaxed, fun setting. Still time to join: https://bit.ly/3HbTbu1 Questions? Contact Caroline Romanelli #LifeScience #MaxCyte #KACTUS #I270Labs #BiotechNetworking #HappyHourVibes
-
-
In this latest Biocompare feature, MaxCyte's SVP of Technical Applications & Customer Support, James Brady, PhD, shares insights on advancing upstream manufacturing for cell-based gene therapies. In it he highlights: - How advanced process analytics, like real-time, in-line sensors, are transforming process monitoring with feedback loops that speed development and boost efficacy. - How optimized cell isolation and expansion protocols, guided by advances in cell biology and immunology, are ensuring maximal therapeutic potency. Read the article: https://bit.ly/478hLXb #GeneTherapy #CellTherapy #Bioprocessing #UpstreamManufacturing #MaxCyte #ProcessAnalytics
-
Facing low gene editing efficiency or poor cell viability? 📅 Join us on Thursday, Sept 4 | 4–5pm ET for a webinar with Peter Gee, PhD, Regional Manager, Field Applications Scientists, APAC, at MaxCyte. Discover how MaxCyte’s Flow Electroporation® technology helps you overcome the limits of chemical transfection and retroviral transduction for plasmid DNA, mRNA, and CRISPR-RNP delivery — at any scale. ✅ Learn about: - Achieving consistent results from thousands to millions of cells. - Large-scale electroporation to save weeks in development. Register now: https://bit.ly/3Jsyzye #GeneEditing #Electroporation #CellEngineering #LifeSciences #CRISPR #GeneTherapy #CellTherapy
-
-
One week to go until the MaxCyte x KACTUS x I-270 Innovation LABS summer happy hour! 🎯 Whether you’re a cell therapy pro, protein production expert, or just curious about the biotech scene, this is your chance to meet, mingle, and enjoy a summer evening with peers. 📅 Wednesday, August 27 | 4:00pm ET 📍 Frederick, MD We’ll bring the food, drinks & raffle prizes — you bring the conversation. Sign up before spots fill: https://bit.ly/3HbTbu1 Questions? Contact Caroline Romanelli #LifeScience #Networking #MaxCyte #KACTUS #I270Labs #HappyHourVibes
-
-
Last week, our Field Applications Scientist, Megan Embrey, joined the Cell & Gene Tech Expo to give attendees a quick tour of MaxCyte’s ExPERT® platform and share how we support partners from concept to clinic. If you missed it, don’t worry—the full recording will be available soon in our Learning Hub, where you can already explore webinars, events, and resources on cell therapy solutions. Follow MaxCyte to be the first to know when Megan’s session is live, and keep learning with us: https://bit.ly/4fJEmeL
-
Congratulations to our partner Anocca on reaching an important milestone as they advance their first-in-human clinical trial for VIDAR-1, a pioneering non-viral gene-edited TCR-T therapy for pancreatic cancer.
PRESS RELEASE: Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer We are pleased to announce that we have raised SEK 440mn to advance our VIDAR-1 clinical programme targeting pancreatic cancer. #ANOC001, the first product in the #VIDAR1 programme targets KRAS G12V mutation, and will represent the first human trial for a non-viral gene-edited TCR-T cell therapy in Europe. Recruitment is now open for Phase I of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and Netherlands. We look forward to advancing this program to address the high unmet medical need in patients with pancreatic cancer. 🔗 Read the full press release: https://lnkd.in/duZNM45k
-
From inspiring talks to cutting-edge research, it is amazing connecting with brilliant minds shaping the future of biotech at Genome Engineering: CRISPR Frontiers at Cold Spring Harbor Laboratory! We were happy to host a dynamic lunch-hour workshop designed for gene editing researchers eager to explore the latest in non-viral delivery and precision genome engineering. “Empowering Gene Editing Workflows: Real-Time Electroporation & Off-Target Analysis” with Nitin Kulkarni, PhD, Senior Application Scientist and Doug Smith, PhD, SVP, Science and Innovation. The session featured a live demonstration of the MaxCyte® platform, showcasing its high-performance electroporation technology, followed by a scientific presentation on SeQure DX™, our advanced analytics solution for off-target detection and genome integrity assessment. Stop by our booth in the next couple days, if you haven’t had the chance to yet! 🧬🧫 #crispr #cshl #cellengineering
-
-
On the heels of our recent Adicet Bio partnership, MaxCyte’s Senior Director of Innovation and Business Development Sean Menarguez shares the future of off-the-shelf T-cell therapies in this latest piece from BioProcess Insider. Learn more about: - How next-generation, non-viral T-cell platforms are shaping the landscape for scalable, allogeneic therapies - Why electroporation technology is enabling high-efficiency, non-viral cell engineering at clinical scale - What’s next for bridging innovative, non-viral research with real-world patient impact Read the full article here: https://bit.ly/4oGZbMc #CellTherapy #AllogeneicTCells #GeneEditing #FlowElectroporation #MaxCyte